Abstract
Androgenetic alopecia (AGA) is the most common form of alopecia in men. Cetirizine, a second-generation H1 blocker, is known for its anti-inflammatory properties and its ability to decrease prostaglandin D2 (PGD2) production. To evaluate the efficacy and tolerability of topical cetirizine in male patients with AGA. Two groups of 30 patients each (healthy males aged between 22 and 55years) with different grades of AGA classified according to the Hamilton-Norwood classification were recruited for this study. Group A subjects applied 1mL of 1% topical cetirizine daily, while group B subjects served as controls and were instructed to apply 1mL of a placebo solution for 6months. Dermoscopic assessment revealed significantly higher hair regrowth among the cetirizine-treated group (P<.001). The patients' satisfaction was significantly higher among the cetirizine-treated group (P<.001). The current study highlights a potential role cetirizine might have in treating AGA. It should be noted that studies are lacking in this regard and more randomized and controlled trials are warranted in order to confirm or refute such early findings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
